TW202328162A - 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 - Google Patents

新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 Download PDF

Info

Publication number
TW202328162A
TW202328162A TW111149562A TW111149562A TW202328162A TW 202328162 A TW202328162 A TW 202328162A TW 111149562 A TW111149562 A TW 111149562A TW 111149562 A TW111149562 A TW 111149562A TW 202328162 A TW202328162 A TW 202328162A
Authority
TW
Taiwan
Prior art keywords
compound
structural formula
antibody
immunoconjugate
alkyl
Prior art date
Application number
TW111149562A
Other languages
English (en)
Chinese (zh)
Inventor
理察 H 李
東駿 李
Original Assignee
美商艾德森特克斯治療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾德森特克斯治療股份有限公司 filed Critical 美商艾德森特克斯治療股份有限公司
Publication of TW202328162A publication Critical patent/TW202328162A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW111149562A 2021-12-23 2022-12-22 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物 TW202328162A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293583P 2021-12-23 2021-12-23
US63/293,583 2021-12-23

Publications (1)

Publication Number Publication Date
TW202328162A true TW202328162A (zh) 2023-07-16

Family

ID=86903604

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111149562A TW202328162A (zh) 2021-12-23 2022-12-22 新穎的澳瑞他汀(auristatin)類似物及其免疫綴合物

Country Status (10)

Country Link
US (1) US20250049937A1 (cg-RX-API-DMAC7.html)
EP (1) EP4453000A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025500404A (cg-RX-API-DMAC7.html)
KR (1) KR20240152826A (cg-RX-API-DMAC7.html)
CN (1) CN118829645A (cg-RX-API-DMAC7.html)
AU (1) AU2022422015A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241878A1 (cg-RX-API-DMAC7.html)
IL (1) IL313784A (cg-RX-API-DMAC7.html)
TW (1) TW202328162A (cg-RX-API-DMAC7.html)
WO (1) WO2023122228A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786483A1 (en) 2023-09-26 2026-08-05 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Auristatin derivative and antibody-drug conjugate thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
US9884817B2 (en) * 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途

Also Published As

Publication number Publication date
EP4453000A4 (en) 2025-12-24
AU2022422015A1 (en) 2024-07-04
JP2025500404A (ja) 2025-01-09
WO2023122228A1 (en) 2023-06-29
CN118829645A (zh) 2024-10-22
US20250049937A1 (en) 2025-02-13
KR20240152826A (ko) 2024-10-22
CA3241878A1 (en) 2023-06-29
IL313784A (en) 2024-08-01
EP4453000A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
AU2020263231B2 (en) Camptothecin derivatives
TWI712605B (zh) 含有cti藥效基團之雙功能性細胞毒性劑
CA3027178A1 (en) Anti-egfr antibody drug conjugates
CA2951368A1 (en) Auristatin derivatives and conjugates thereof
WO2024059236A1 (en) Novel camptothecin analogs and immunoconjugates thereof
WO2024193692A1 (zh) 连接子及其在配体药物偶联物中的应用
TW202400266A (zh) 配體藥物偶聯物及其應用
TW202608866A (zh) 包含sting促效劑之抗體藥物結合物及其用途
AU2022422015A1 (en) Novel auristatin analogs and immunoconjugates thereof
CN119300868B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
IL312533A (en) Novel auristatin analogs and immunoconjugates thereof
KR20250049520A (ko) 인간 trop2에 대한 항체를 포함하는 항체-약물 접합체 및 이의 용도
HK40117241A (en) Novel auristatin analogs and immunoconjugates thereof
CA3137125C (en) Camptothecin derivatives
RU2844846C2 (ru) Производные камптотецина
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40115429A (en) Novel auristatin analogs and immunoconjugates thereof
HK40104845A (en) Camptothecin derivatives
TW202313125A (zh) 一種抗腫瘤化合物及其應用
HK40069519B (en) Camptothecin derivatives
HK40069519A (en) Camptothecin derivatives